Key result
Azimilide cuts symptomatic arrhythmia recurrence risk ~37% vs placebo.
Why the study?
Atrial fibrillation is an increasingly common rhythm disorder causing symptoms in most patients, and new antiarrhythmic therapies are needed.
Does azimilide reduce symptomatic arrhythmia recurrences in patients with atrial fibrillation or atrial flutter?
RCT (n=384)
Randomized
Does azimilide reduce symptomatic arrhythmia recurrences in patients with atrial fibrillation or atrial flutter?
Hazard Ratio: 1.58 (95% CI 1.15–2.16)
p-value: p=0.005
Azimilide at doses of 100 mg and 125 mg daily significantly prolongs the time to first symptomatic arrhythmia recurrence in patients with atrial fibrillation or flutter.
No takes yet. Share an insight, caveat, or question.
May support higher-dose azimilide for AF recurrence prevention; hypothesis-generating and should not yet change practice.
Pritchett et al. (2000) conducted an RCT in Atrial fibrillation, atrial flutter or both (n=384). Azimilide vs. Placebo was evaluated on Time to first symptomatic recurrence (HR 1.58, 95% CI 1.15-2.16, p=0.005). Azimilide 100 mg and 125 mg daily significantly prolonged the time to first symptomatic arrhythmia recurrence compared with placebo (HR [placebo:azimilide] 1.58; 95% CI 1.15-2.16; p=0.005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: